Sippy Punn

A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors

L. Saltz, N. Raj, M. Capanu, 2022, JCO oncology practice.

Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas

N. Raj, P. Munster, L. Fong, 2023, British Journal of Cancer.

Response to Repotrectinib After Development of NTRK Resistance Mutations on First- and Second-Generation TRK Inhibitors.

A. Drilon, M. Kris, N. Raj, 2023, JCO precision oncology.

Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms.

Ritika Kundra, N. Raj, M. Capanu, 2024, Endocrine-related cancer.